These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 425688)

  • 21. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
    Zhou H; Wu X; Lu X; Chen G; Ye X; Huang J
    Thromb Res; 2009; 123(3):537-42. PubMed ID: 18691743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The plasma levels of urokinase plasminogen activator and plasminogen activator inhibitor-1 and the protein expressions of alpha-SMA and MMP-1 and TIMP-1 in patients with different grades of liver fibrosis].
    Bai K; Guo CJ
    Zhonghua Gan Zang Bing Za Zhi; 2006 Jun; 14(6):459-61. PubMed ID: 16792874
    [No Abstract]   [Full Text] [Related]  

  • 23. [Method of determining the activity of histidase in small volumes of blood].
    Tabolin VA; Smirnova TA; Burobin VA
    Lab Delo; 1977; (1):28-9. PubMed ID: 67244
    [No Abstract]   [Full Text] [Related]  

  • 24. Diagnostic efficacy of plasma urokinase-type plasminogen activator and plasminogen activator inhibitor-2 in differentiation of hepatocellular carcinoma from cirrhosis.
    Song KS; Lee A; Choi JR; Kwon OH
    Thromb Haemost; 1995 Sep; 74(3):864-7. PubMed ID: 8571313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B].
    Wu XR; Wang Q; Shi SS; Lu MH; Guo WD
    Zhonghua Gan Zang Bing Za Zhi; 2004 Feb; 12(2):82-4. PubMed ID: 14980106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of vitamin E on the activity of various liver enzymes and the role of lipid peroxides in the pathogenesis of viral hepatitis].
    Abagian IA; Kazazian AV; Mkhitarian VG
    Zh Eksp Klin Med; 1976; 16(1):73-7. PubMed ID: 1025979
    [No Abstract]   [Full Text] [Related]  

  • 27. [Zonal distribution of haptoglobin and ceruloplasmin synthesis in the liver].
    Volkova ZI
    Vopr Med Khim; 1976; 22(2):171-6. PubMed ID: 1030885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Changes in the activity of organ-specific liver enzyme histidase in experimental acute pancreatitis].
    Synovets AS; Michurin VF
    Klin Khir (1962); 1982 Nov; (11):66-7. PubMed ID: 7154540
    [No Abstract]   [Full Text] [Related]  

  • 29. [Study of an enzyme complex in rheumatism in children and adults].
    Karpocheva MP; Kaĭnova AS; Pankina VKh
    Vrach Delo; 1974 May; 5(0):69-72. PubMed ID: 4152193
    [No Abstract]   [Full Text] [Related]  

  • 30. [Dynamics of organ-specific liver enzymes and urocanic acid in patients with gout during complex balneotherapy].
    Tsarfis PG; Fedorova NE; Korliakova OV; Siluianova SN; Burobin VA
    Vopr Kurortol Fizioter Lech Fiz Kult; 1987; (5):37-40. PubMed ID: 2893488
    [No Abstract]   [Full Text] [Related]  

  • 31. Increased plasma levels of urokinase-type plasminogen activator with endometrial and cervical cancer.
    Koelbl H; Kirchheimer JC; Tatra G; Christ G; Binder BR
    Obstet Gynecol; 1988 Aug; 72(2):252-6. PubMed ID: 3134631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Serum acetylcholinesterase activity in various skin diseases].
    Kipping D
    Z Haut Geschlechtskr; 1968 Oct; 43(19):811-6. PubMed ID: 5723218
    [No Abstract]   [Full Text] [Related]  

  • 33. [The plasma levels of transforming growth factor beta1 and the protein expressions of alpha-SMA, urokinase plasminogen activator and plasminogen activator inhibitor-1 in liver of patients with different grades of hepatic fibrosis].
    Wu XR; Lv MH; Wang Q; Shi SS; Guo WD
    Zhonghua Gan Zang Bing Za Zhi; 2004 Jul; 12(7):400-2. PubMed ID: 15268802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Diagnosis of functional liver disorders in gastroduodenal ulcers].
    Ashrapova MA; Abdullaev NKh; Akhsan DN
    Klin Khir (1962); 1985; (8):25-6. PubMed ID: 2865390
    [No Abstract]   [Full Text] [Related]  

  • 35. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
    Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
    Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance of plasma tissue factor pathway and urokinase-type plasminogen activator system in cancer patients.
    Zhao W; Wang X; Qu B; Huang X; Wang H
    Chin Med J (Engl); 2002 May; 115(5):702-4. PubMed ID: 12133538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [State of the liver in Itsenko-Cushing syndrome].
    Kalinin AP; Drozdova GA; Gurevich EG
    Sov Med; 1974 Jun; 37(6):87-90. PubMed ID: 4367735
    [No Abstract]   [Full Text] [Related]  

  • 38. [Inhibition by ethanol and acetaldehyde the plasmin activity and plasminogen activation induced by urokinase and streptokinase].
    Roszkowska-Jakimiec W; Jurkowski J; Ostrowska H; Worowski K
    Rocz Akad Med Bialymst (1989); 1988-1989; 33-34():53-66. PubMed ID: 2979011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urokinase antigen in plasma of patients with liver cirrhosis and hepatoma.
    Kirchheimer JC; Huber K; Polterauer P; Binder BR
    Thromb Haemost; 1985 Oct; 54(3):617-8. PubMed ID: 3003953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urokinase-type plasminogen activator, plasminogen activator inhibitor type 1 and cathepsin D: analysis of their prognostic significance in squamous cell carcinoma of the head and neck.
    Strojan P; Budihna M; Smid L; Vrhovec I; Skrk J
    Anticancer Res; 2000; 20(5C):3975-81. PubMed ID: 11268487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.